NANOBIOTIX Stock Drops 8.46% at Midday Friday, Hindered by Clinical Trial Transfer
Nanobiotix shows a significantly negative performance this midday Friday, with the stock dropping 8.46% to trade at €16.24, down from €17.74 at close on Thursday. The movement is part of a marked downtrend in the medium term, with a decline of 31.62% over the past week. This correction coincides with the completion of the transfer of its clinical trial to Johnson & Johnson, announced earlier in the week.
Sustained Selling Pressure Confirmed in Friday's Session
This Friday's session confirms sustained selling pressure on the stock, with 3.16% of the capital traded on the markets, illustrating active investor participation. In the short term, the weekly performance is distinctly negative, even though the stock maintains a largely positive long-term record: +227.4% over three months and +262.7% over twelve months. This volatility reflects the market's strong reactivity to events affecting the clinical pipeline or the company's structure. For comparison, the CAC 40 index shows a more moderate decline of 0.52% in the same session, highlighting a specific underperformance by Nanobiotix. The stock's implied volatility peaks at 34.76% over a month, reflecting significant uncertainty about short-term prospects. Since the beginning of the year, the stock has significantly outperformed the broad index, benefiting from the positive dynamics of the biotech sector, before this correction.
Nanobiotix Completes Clinical Trial Sponsorship Transfer to Johnson & Johnson
Nanobiotix has finalized the transfer of sponsorship of the NANORAY-312 clinical trial to Johnson & Johnson, also transferring operational control of the program to the pharmaceutical giant. This event, which occurred earlier in the week, has led to adjustments in the group's clinical schedule, fueling questions about the exact timing of data publication. Investors had previously anticipated the recruitment of the last patient by the first half of 2026, followed by the disclosure of results. This strategic transfer marks a major evolution in the program's governance and creates a period of uncertainty about the upcoming steps, partly explaining the selling dynamics observed this week. The context remains that of a reorientation of the group's operational model towards closer collaboration with a major industry player.
Technical Analysis of Nanobiotix Stock
From a technical standpoint, Nanobiotix is trading above its 200-day moving average set at €6.13, but remains significantly behind its 50-day average positioned at €13.05. The stock is framed by its Bollinger bands, with a lower threshold at €12.99 and a ceiling at €26.67, the current level of €16.24 fitting into a median zone. The Relative Strength Index (RSI) is at 52, indicating a neutral configuration. The MACD shows a bearish setup with its signal line at 3.04 versus a main line at 2.28, confirming the selling pressure. The major technical thresholds remain the support at €7.95 and the resistance at €24.45.
